ESMO, the European professional organisation for medical oncology, has launched the first eUpdates for its world-renowned ESMO Clinical Practice Guidelines (CPG).
eUpdates will be published on the ESMO website to provide CPG users with timely updates each time breakthrough necessitating rapid communication has occurred and when a Magnitude of Clinical Benefit Scale (MCBS) score has been produced for a new European Medicines Agency (EMA) therapy or a new indication.
The ESMO CPG on Cutaneous Melanoma is the first to benefit from eUpdates including the MCBS grading of the PD-1 checkpoint inhibitor nivolumab to reflect the rapidly growing body of evidence on the use of immunotherapy for this type of skin cancer and the recent approval of this therapy by the EMA. The second eUpdate for this CPG will provide practical diagnostic and treatment algorithms.
The one page summary includes information on why an update was needed, recommendations for treatment, the ESMO MCBS scoring table, where applicable, as well as references.
In 2016, ESMO will release a total of 11 new and updated CPGs, with an improved format which includes standardised treatment management algorithms and flow-charts, personalised medicine synopsis tables and a MCBS scores for new therapies/indications approved by the EMA. The first CPGs integrating an MCBS score for newly EMA approved indications will be published in a supplement to the October issue of Annals of Oncology.
Brought to you by Scope e-Knowledge Center, a world-leading provider of metadata services, abstraction, indexing, entity extraction and knowledge organisation models (Taxonomies, Thesauri and Ontologies).
